GSK, J&J Plan Filings For Third-To-Market IL-6 Inhibitor Sirukumab

GlaxoSmithKline PLC and Janssen Biologics, a Johnson & Johnson subsidiary, will seek regulatory approvals for sirukumab in 2016 based on positive Phase III results in rheumatoid arthritis, setting the biologic up to compete with two other interleukin-6 (IL-6) inhibitors when it hits the market in 2017.

GlaxoSmithKline PLC and Janssen Biologics, a Johnson & Johnson subsidiary, will seek regulatory approvals for sirukumab in 2016 based on positive Phase III results in rheumatoid arthritis, setting the biologic up to compete with two other interleukin-6 (IL-6) inhibitors when it hits the market in 2017.

More from Immunological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.